BioMarin Pharmaceutical (NASDAQ:BMRN) Now Covered by UBS Group

Key Points

• UBS Group initiated coverage of BioMarin Pharmaceutical with a “buy” rating and an $88 price target, implying approximately 55% upside from the reported share price of $56.65.
• Analyst sentiment is broadly positive: BioMarin has a consensus “Moderate Buy” rating and an average price target of $88.87, with recent upgrades from Raymond James and Wall Street Zen.
• BioMarin reported quarterly EPS of $1.20, beating estimates of $0.95, while revenue rose 20% year over year to $989.71 million; institutional investors own approximately 98.7% of the company.

Stock analysts at UBS Group initiated coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) in a note issued to investors on Thursday. The brokerage set a "buy" rating and a $88.00 price target on the biotechnology company's stock. UBS Group's price target would indicate a potential upside of 55.34% from the company's current price.

Several other equities research analysts have also issued reports on the stock. Citigroup lifted their price target on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the company a "buy" rating in a research note on Thursday, July 16th. Raymond James Financial raised BioMarin Pharmaceutical from an "outperform" rating to a "strong-buy" rating and set a $109.00 target price on the stock in a research report on Monday. Wall Street Zen upgraded BioMarin Pharmaceutical from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. Royal Bank Of Canada decreased their target price on shares of BioMarin Pharmaceutical from $66.00 to $62.00 and set a "sector perform" rating for the company in a research note on Tuesday, July 7th. Finally, BMO Capital Markets restated an "outperform" rating on shares of BioMarin Pharmaceutical in a report on Wednesday, September 16th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $88.87.

BioMarin Pharmaceutical Stock Up 2.7%

BMRN traded up $1.51 during trading on Thursday, hitting $56.65. The company had a trading volume of 603,651 shares, compared to its average volume of 2,074,614. The company has a market capitalization of $10.97 billion, a PE ratio of 152.96, a PEG ratio of 0.37 and a beta of 0.22. BioMarin Pharmaceutical has a one year low of $49.26 and a one year high of $70.98. The firm's 50-day moving average price is $63.30 and its 200 day moving average price is $58.67. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. The firm had revenue of $989.71 million for the quarter, compared to the consensus estimate of $932.03 million. During the same quarter last year, the business posted $1.44 EPS. The company's revenue for the quarter was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. As a group, equities analysts expect that BioMarin Pharmaceutical will post 4.10 earnings per share for the current year.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Several institutional investors and hedge funds have recently made changes to their positions in the company. Parkside Financial Bank & Trust boosted its stake in shares of BioMarin Pharmaceutical by 70.3% in the 2nd quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company's stock valued at $26,000 after purchasing an additional 187 shares in the last quarter. Chicago Partners Investment Group LLC boosted its holdings in shares of BioMarin Pharmaceutical by 2.4% during the 1st quarter. Chicago Partners Investment Group LLC now owns 12,183 shares of the biotechnology company's stock valued at $660,000 after acquiring an additional 290 shares in the last quarter. 4WEALTH Advisors Inc. increased its holdings in BioMarin Pharmaceutical by 8.8% in the 1st quarter. 4WEALTH Advisors Inc. now owns 3,880 shares of the biotechnology company's stock worth $213,000 after purchasing an additional 313 shares in the last quarter. Parallel Advisors LLC increased its holdings in BioMarin Pharmaceutical by 33.9% in the 1st quarter. Parallel Advisors LLC now owns 1,768 shares of the biotechnology company's stock worth $100,000 after purchasing an additional 448 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. raised its position in BioMarin Pharmaceutical by 4.3% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 12,200 shares of the biotechnology company's stock valued at $689,000 after purchasing an additional 500 shares during the last quarter. Institutional investors and hedge funds own 98.71% of the company's stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company that develops and commercializes therapies for rare and serious genetic diseases. The company focuses on conditions with limited treatment options, using approaches that include enzyme replacement therapy, small-molecule medicines, biologics and gene therapy.

Its products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for CLN2 disease, Palynziq and Kuvan for phenylketonuria, and Voxzogo for children with achondroplasia and open growth plates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.